187 related articles for article (PubMed ID: 16183931)
1. Functional CT for quantifying tumor perfusion in antiangiogenic therapy in a rat model.
Kan Z; Phongkitkarun S; Kobayashi S; Tang Y; Ellis LM; Lee TY; Charnsangavej C
Radiology; 2005 Oct; 237(1):151-8. PubMed ID: 16183931
[TBL] [Abstract][Full Text] [Related]
2. FN13762 murine breast cancer: region-by-region correlation of first-pass perfusion CT indexes with histologic vascular parameters.
Park CM; Goo JM; Lee HJ; Kim MA; Kim HC; Kim KG; Lee CH; Im JG
Radiology; 2009 Jun; 251(3):721-30. PubMed ID: 19474375
[TBL] [Abstract][Full Text] [Related]
3. Functional CT quantification of tumor perfusion after transhepatic arterial embolization in a rat model.
Kan Z; Kobayashi S; Phongkitkarun S; Charnsangavej C
Radiology; 2005 Oct; 237(1):144-50. PubMed ID: 16183930
[TBL] [Abstract][Full Text] [Related]
4. Quantification of angiogenesis by functional computed tomography in a Matrigel model in rats.
Phongkitkarun S; Kobayashi S; Kan Z; Lee TY; Charnsangavej C
Acad Radiol; 2004 May; 11(5):573-82. PubMed ID: 15147622
[TBL] [Abstract][Full Text] [Related]
5. Vascular endothelial growth factor-mediated angiogenesis inhibition and postoperative wound healing in rats.
Roman CD; Choy H; Nanney L; Riordan C; Parman K; Johnson D; Beauchamp RD
J Surg Res; 2002 Jun; 105(1):43-7. PubMed ID: 12069500
[TBL] [Abstract][Full Text] [Related]
6. Dynamic contrast-enhanced micro-computed tomography correlates with 3-dimensional fluorescence ultramicroscopy in antiangiogenic therapy of breast cancer xenografts.
Pöschinger T; Renner A; Eisa F; Dobosz M; Strobel S; Weber TG; Brauweiler R; Kalender WA; Scheuer W
Invest Radiol; 2014 Jul; 49(7):445-56. PubMed ID: 24598441
[TBL] [Abstract][Full Text] [Related]
7. Novel Phase I dose de-escalation design trial to determine the biological modulatory dose of the antiangiogenic agent SU5416.
Dowlati A; Robertson K; Radivoyevitch T; Waas J; Ziats NP; Hartman P; Abdul-Karim FW; Wasman JK; Jesberger J; Lewin J; McCrae K; Ivy P; Remick SC
Clin Cancer Res; 2005 Nov; 11(21):7938-44. PubMed ID: 16278419
[TBL] [Abstract][Full Text] [Related]
8. Irradiation combined with SU5416: microvascular changes and growth delay in a human xenograft glioblastoma tumor line.
Schuuring J; Bussink J; Bernsen HJ; Peeters W; van Der Kogel AJ
Int J Radiat Oncol Biol Phys; 2005 Feb; 61(2):529-34. PubMed ID: 15667976
[TBL] [Abstract][Full Text] [Related]
9. Flk-1 specific kinase inhibitor (SU5416) inhibited the growth of GS-9L glioma in rat brain and prolonged the survival.
Takamoto T; Sasaki M; Kuno T; Tamaki N
Kobe J Med Sci; 2001 Aug; 47(4):181-91. PubMed ID: 11733657
[TBL] [Abstract][Full Text] [Related]
10. [Feasibility of volume perfusion CT (VPCT) imaging in antiangiogenic treatment of rabbit VX2 soft-tissue tumor].
Yang P; Feng XW; Ye ZX; Li XB; Hou Y; Liu YT; Xiao JY
Zhonghua Zhong Liu Za Zhi; 2013 May; 35(5):341-6. PubMed ID: 24054009
[TBL] [Abstract][Full Text] [Related]
11. Mechanism of reoxygenation after antiangiogenic therapy using SU5416 and its importance for guiding combined antitumor therapy.
Ansiaux R; Baudelet C; Jordan BF; Crokart N; Martinive P; DeWever J; Grégoire V; Feron O; Gallez B
Cancer Res; 2006 Oct; 66(19):9698-704. PubMed ID: 17018628
[TBL] [Abstract][Full Text] [Related]
12. Pharmacodynamic-mediated effects of the angiogenesis inhibitor SU5416 on the tumor disposition of temozolomide in subcutaneous and intracerebral glioma xenograft models.
Ma J; Li S; Reed K; Guo P; Gallo JM
J Pharmacol Exp Ther; 2003 Jun; 305(3):833-9. PubMed ID: 12626639
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of tumor growth, angiogenesis, and microcirculation by the novel Flk-1 inhibitor SU5416 as assessed by intravital multi-fluorescence videomicroscopy.
Vajkoczy P; Menger MD; Vollmar B; Schilling L; Schmiedek P; Hirth KP; Ullrich A; Fong TA
Neoplasia; 1999 Apr; 1(1):31-41. PubMed ID: 10935468
[TBL] [Abstract][Full Text] [Related]
14. Colorectal tumor vascularity: quantitative assessment with multidetector CT--do tumor perfusion measurements reflect angiogenesis?
Goh V; Halligan S; Daley F; Wellsted DM; Guenther T; Bartram CI
Radiology; 2008 Nov; 249(2):510-7. PubMed ID: 18812560
[TBL] [Abstract][Full Text] [Related]
15. The effects of antiangiogenic compound SU5416 in a rat model of pulmonary arterial hypertension.
Sakao S; Tatsumi K
Respiration; 2011; 81(3):253-61. PubMed ID: 21116108
[TBL] [Abstract][Full Text] [Related]
16. Perfusion parameters as potential imaging biomarkers for the early prediction of radiotherapy response in a rat tumor model.
Lee HY; Kim N; Goo JM; Chie EK; Song HJ
Diagn Interv Radiol; 2016; 22(3):231-40. PubMed ID: 27023149
[TBL] [Abstract][Full Text] [Related]
17. Determinants for in vivo antitumor effect of angiogenesis inhibitor SU5416 formulated in PEGylated emulsion.
Ogawara K; Abe S; Un K; Yoshizawa Y; Kimura T; Higaki K
J Pharm Sci; 2014 Aug; 103(8):2464-9. PubMed ID: 24985750
[TBL] [Abstract][Full Text] [Related]
18. VEGF and angiogenesis in acute and chronic MOG((35-55)) peptide induced EAE.
Roscoe WA; Welsh ME; Carter DE; Karlik SJ
J Neuroimmunol; 2009 Apr; 209(1-2):6-15. PubMed ID: 19233483
[TBL] [Abstract][Full Text] [Related]
19. Inhibitory effects of SU5416, a selective vascular endothelial growth factor receptor tyrosine kinase inhibitor, on experimental corneal neovascularization.
Keskin U; Totan Y; Karadağ R; Erdurmuş M; Aydın B
Ophthalmic Res; 2012; 47(1):13-8. PubMed ID: 21691137
[TBL] [Abstract][Full Text] [Related]
20. Dynamic contrast-enhanced computed tomography imaging biomarkers correlated with immunohistochemistry for monitoring the effects of sorafenib on experimental prostate carcinomas.
Cyran CC; von Einem JC; Paprottka PM; Schwarz B; Ingrisch M; Dietrich O; Hinkel R; Bruns CJ; Clevert DA; Eschbach R; Reiser MF; Wintersperger BJ; Nikolaou K
Invest Radiol; 2012 Jan; 47(1):49-57. PubMed ID: 21934514
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
